Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

Description: Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016

Summary

‘Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016’, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration
- The report reviews pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Wet (Neovascular / Exudative) Macular Degeneration therapeutics and enlists all their major and minor projects
- The report assesses Wet (Neovascular / Exudative) Macular Degeneration therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Wet (Neovascular / Exudative) Macular Degeneration

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Wet (Neovascular / Exudative) Macular Degeneration Overview
Therapeutics Development
Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview
Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development
AciOnt Inc.
Allergan Plc
Amakem NV
Apellis Pharmaceuticals, Inc.
Apexigen, Inc.
Applied Genetic Technologies Corporation
Avalanche Biotechnologies, Inc.
Benitec Biopharma Limited
BIOCAD
Boehringer Ingelheim GmbH
Charlesson LLC.
Chong Kun Dang Pharmaceutical Corp.
Circadian Technologies Limited
Clanotech AB
Clearside BioMedical, Inc.
Coherus BioSciences, Inc.
Daiichi Sankyo Company, Limited
Delenex Therapeutics AG
Eleven Biotherapeutics Inc.
Exonate Limited
F. Hoffmann-La Roche Ltd.
Formycon AG
GTx, Inc.
iCo Therapeutics Inc.
Icon Bioscience, Inc.
Kala Pharmaceuticals, Inc.
Kodiak Sciences, Inc.
Mabion SA
Mitotech S.A.
Neurotech Pharmaceuticals, Inc.
Ocular Therapeutix, Inc.
Ohr Pharmaceutical Inc.
Ophthotech Corp.
Oxford BioMedica Plc
PanOptica, Inc.
Pfenex Inc.
Pfizer Inc.
pSivida Corp.
Quark Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
RXi Pharmaceuticals Corporation
Santen Pharmaceutical Co., Ltd.
Sanwa Kagaku Kenkyusho Co., Ltd.
TRACON Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc.
Tyrogenex, Inc.
Xbrane Biopharma AB

Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics Assessment

Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

(aflibercept + nesvacumab) - Drug Profile
(aflibercept + rinucumab) - Drug Profile
abicipar pegol - Drug Profile
AC-301 - Drug Profile
ACX-107 - Drug Profile
aflibercept - Drug Profile
aflibercept biosimilar - Drug Profile
AGN-151200 - Drug Profile
ALG-1001 - Drug Profile
AMA-0428 - Drug Profile
APL-2 - Drug Profile
APX-003 - Drug Profile
APX-3330 - Drug Profile
AVA-101 - Drug Profile
AVA-201 - Drug Profile
avacincaptad pegol sodium - Drug Profile
AXT-108 - Drug Profile
bertilimumab - Drug Profile
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Apexigen, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Applied Genetic Technologies Corporation, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Avalanche Biotechnologies, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Benitec Biopharma Limited, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by BIOCAD, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Charleson LLC., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Circadian Technologies Limited, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clanotech AB, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Clearside BioMedical, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Coherus BioSciences, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Delenex Therapeutics AG, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Eleven Biotherapeutics Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Exonate Limited, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Formycon AG, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by GTx, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by iCo Therapeutics Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Icon Bioscience, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kala Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Kodiak Sciences, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mabion SA, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Mitotech S.A., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Neurotech Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ocular Therapeutix, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Ophthotech Corp., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Oxford BioMedica Plc, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by PanOptica, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfenex Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Pfizer Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by pSivida Corp., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Quark Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RegenxBio Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by RXi Pharmaceuticals Corporation, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Santen Pharmaceutical Co., Ltd., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by TWi Pharmaceuticals, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Tyrogenex, Inc., H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Pipeline by Xbrane Biopharma AB, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration Therapeutics - Recent Pipeline Updates, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects, H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..1), H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Dormant Projects (Contd..2), H1 2016
Wet (Neovascular / Exudative) Macular Degeneration - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Wet (Neovascular / Exudative) Macular Degeneration, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3665229/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3665229/">http://www.researchandmarkets.com/reports/3665229/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF) -</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprise-wide:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr ☐</th>
<th>Mrs ☐</th>
<th>Dr ☐</th>
<th>Miss ☐</th>
<th>Ms ☐</th>
<th>Prof ☐</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>__________________________</td>
<td>Last Name:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>__________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ___________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World